Literature DB >> 11989551

Lipoprotein abnormalities in patients with secondary renal amyloidosis.

K Cengiz1, A Bakan, H Yilmaz.   

Abstract

The prevalance of hyperlipidemia in chronic renal failure (CRF) patients is higher than in general population. Secondary amyloidosis is a common cause of CRF in Turkey. In this study, 25 patients with CRF due to secondary renal amyloidosis (amyloid-CRF), 15 patients with CRF without amyloidosis-CRF and 17 healthy controls were studied for serum lipid parameters. The mean serum lipoprotein (a) [LP(a)] level in the patients with amyloid-CRF was significantly higher than in the controls (p < 0.01). The mean serum apolipoprotein B (Apo B), apolipoprotein E (Apo E) and triglyceride levels in the patients with amyloid-CRF were very significantly higher than in the controls (p < 0.001). The mean serum total cholesterol, low-density lipoprotein (LDL) levels in the patients with amyloid-CRF were higher than in the controls (p < 0.05). The mean serum apo AI levels in the patients with amyloid-CRF was very significantly lower than in the controls (p < 0.001). The mean serum high-density lipoprotein (HDL) in the patients with amyloid-CRF was lower than in the controls (p < 0.05). The mean serum Lp (a), Apo AI, Apo B and Apo E levels in the patients with amyloid-CRF were significantly higher than in the patients with CRF (p < 0.01). The mean serum total cholesterol, trigliserides, LDL and HDL levels in the patients with amyloid-CRF were higher than in the patients with CRF (p < 0.05). There was not any correlation with serum lipid parameters and serum albumin and urine protein levels (p > 0.05). Our study suggests that serum lipid parameters are abnormal and might be the risk factor of atherosclerotic vascular disease and contribute to renal disease progression in the patients with secondary renal amyloidosis and lipid abnormalities were different from CRF with various etiology, without amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11989551     DOI: 10.1023/a:1014476407047

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  11 in total

1.  A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy.

Authors:  W C Nichols; R E Gregg; H B Brewer; M D Benson
Journal:  Genomics       Date:  1990-10       Impact factor: 5.736

2.  Metabolism of normal and Met30 transthyretin.

Authors:  D Hanes; L A Zech; J Murrell; M D Benson
Journal:  Adv Food Nutr Res       Date:  1996

Review 3.  Hyperlipidemia in patients with chronic renal disease.

Authors:  B L Kasiske
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

4.  Apolipoprotein AI and amyloidosis: a genetic model for aging.

Authors:  M D Benson
Journal:  Kidney Int       Date:  1998-02       Impact factor: 10.612

5.  Lp(a) concentration and serum albumin in haemodialysis patients.

Authors:  M Elisaf; K Katopodis; K C Siamopoulos
Journal:  Nephrol Dial Transplant       Date:  1996-05       Impact factor: 5.992

6.  Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I.

Authors:  M R Persey; D R Booth; S E Booth; R van Zyl-Smit; B K Adams; A B Fattaar; G A Tennent; P N Hawkins; M B Pepys
Journal:  Kidney Int       Date:  1998-02       Impact factor: 10.612

7.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

8.  Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis.

Authors:  K C Siamopoulos; M S Elisaf; H T Bairaktari; M B Pappas; G D Sferopoulos; N G Nikolakakis
Journal:  Perit Dial Int       Date:  1995 Oct-Dec       Impact factor: 1.756

9.  Variant apolipoprotein AI as a major constituent of a human hereditary amyloid.

Authors:  W C Nichols; F E Dwulet; J Liepnieks; M D Benson
Journal:  Biochem Biophys Res Commun       Date:  1988-10-31       Impact factor: 3.575

10.  The interaction of human serum albumin in the native and fully reduced states with apolipoprotein E, serum amyloid protein and very low density lipoproteins from human plasma.

Authors:  A D Dergunov; Y Y Vorotnikova
Journal:  Int J Biochem       Date:  1994-07
View more
  1 in total

1.  Revisiting secondary amyloidosis for an inadequately investigated feature: dyslipidemia.

Authors:  Serhan Piskinpasa; Hadim Akoglu; Eyup Koc; Fatma Dogru; Ezgi Yenigun Coskun; Didem Turgut; Nihal Ozkayar; Ramazan Ozturk; Ali Riza Odabas; Fatih Dede
Journal:  Rheumatol Int       Date:  2012-07-31       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.